Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT7 | O95251 | 19/20 | 0.53 |
| ▸ | KAT6A | Q92794 | 19/20 | 0.53 |
| ▸ | KAT6B | Q8WYB5 | 16/20 | 0.53 |
| ▸ | KAT5 | Q92993 | 12/20 | 0.51 |
| ▸ | KAT8 | Q9H7Z6 | 12/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23635965 | 0.86 | KDM4E (0.52) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL23635952 | 0.85 | KAT7 (0.58) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL27097756 | 0.82 | KDM4E (0.59) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL23635961 | 0.74 | KDM4E (0.44) | KAT7KAT6AKAT6BKDM4EALDH1A1 | |
| SCHEMBL23631832 | 0.73 | GLS (0.46) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30842116 | 0.72 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL23635969 | 0.72 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL23292605 | 0.71 | KMT2A (0.48) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL23635987 | 0.71 | RXFP1 (0.44) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL26077137 | 0.70 | KAT7 (0.63) | KAT7KAT6AKAT6BKAT5KAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-20210213004-A1 | Compounds | CTXT PTY LTD (AU) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210213004-A1 | Compounds | SLC10A1, ABCB11, REN | KAT7 490/4885KAT6A 951/4885KAT6B 766/4885 |
| US-11911372-B2 | Compounds | SLC10A1, ABCB11, REN | KAT7 490/4885KAT6A 951/4885KAT6B 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.